The U.S. Food and Drug Administration on Monday approved Mirati Therapeutics Inc’s lung cancer drug adagrasib, according to the health regulator’s website.
About the Author
The U.S. Food and Drug Administration on Monday approved Mirati Therapeutics Inc’s lung cancer drug adagrasib, according to the health regulator’s website.
